Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives

Frontiers in Oncology

卷:9

Vincenzo Ciminale¹  Loredana Urso¹  Giulia Pasello²  Evgeniya Sharova²  Ilaria Cavallari² 

[1] Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy;

[2] Immunologia e Diagnostica Molecolare Oncologica (IDMO), Istituto Oncologico Veneto IOV- IRCCS, Padova, Italy;

关键词: microRNA;    prognostic stratification;    early diagnosis;    asbestos exposure;    liquid biopsy;    mesothelioma;   

DOI  :  10.3389/fonc.2019.00740

来源: DOAJ

【 摘 要 】

Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. Although the risk factors for MPM are well-known, the majority of MPM patients are diagnosed at an advanced stage and have a very poor prognosis. Circulating biomarkers for early diagnosis remain to be identified, and the current standard for MPM diagnosis relies on pleural biopsies. Robust non-invasive tests for the screening of asbestos-exposed subjects are therefore an important unmet clinical need. This review provides a critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients.

【 授权许可】

Unknown